RECRUITING

A Study to Evaluate the Relative Bioavailability of Povetacicept Formulations and Bioequivalence of Povetacicept Presentations

Description

The purpose of this study is to evaluate the relative bioavailability of Povetacicept formulations, bioequivalence of Povetacicept presentations, and safety and tolerability of Povetacicept.

Conditions

Healthy Volunteers
Talk to us

Related Conditions:

Healthy Volunteers

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to evaluate the relative bioavailability of Povetacicept formulations, bioequivalence of Povetacicept presentations, and safety and tolerability of Povetacicept.

A Phase 1, Open-label, Randomized, 2-part Study to Evaluate the Relative Bioavailability of Povetacicept Formulations and Bioequivalence of Povetacicept Presentations in Healthy Subjects

A Study to Evaluate the Relative Bioavailability of Povetacicept Formulations and Bioequivalence of Povetacicept Presentations

Condition
Healthy Volunteers
Intervention / Treatment

-

Contacts and Locations

Lincoln

Celerion - Lincoln, Lincoln, Nebraska, United States, 68502

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Body mass index (BMI) of 18.0 to 32.0 kilogram per meter square (kg/m\^2), inclusive
  • * A total body weight of more than (\>) 50 kg
  • * History of febrile illness that has not fully resolved within 14 days before the dose of study drug.
  • * Immunization with a live vaccine within 45 days before study drug administration or a non live vaccine within 14 days before study drug administration.

Ages Eligible for Study

18 Years to 55 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Vertex Pharmaceuticals Incorporated,

Study Record Dates

2025-08-27